This site is intended for healthcare professionals only
DiabetesontheNet Logo
Share this article

Linagliptin adds no benefit in high renal risk patients

By Colin Kenny, Editor – Diabetes Distilled

The Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk (CARMELINA) study compared the effect of linagliptin with placebo on cardiovascular (CV) outcomes in adults with type 2 diabetes and high CV risk. The majority of participants also had kidney disease. Researchers found that, when added to usual care, linagliptin was non-inferior to placebo for the primary outcome of major adverse cardiac events but did not show CV benefit. 

CARMELINA evaluated the effect of linagliptin, a selective dipeptidyl peptidase-4 (DPP-4) inhibitor, on CV and kidney outcomes in patients with type 2 diabetes at high risk of CV and kidney events. The randomised, non-inferiority trial, which was conducted in 27 countries, recruited adults with type 2 diabetes who had HbA1c levels ranging from 48 mmol/mol (6.5%) to 86 mmol/mol (10.0%), a history of vascular disease, and a urine-to-albumin creatinine ratio >200 mg/g. Patients were randomly allocated to receive linagliptin 5mg once daily (n=3,494) or placebo (n=3,485) in addition to usual care. 
In this patient population, when added to usual care, linagliptin was non-inferior to placebo for the primary outcome of three-point major adverse CV events (CV death, non-fatal myocardial infarction or non-fatal stroke) and did not show evidence of CV benefit over a median of 2.2 years. Compared to placebo, linagliptin had no significant effect on the incidence of composite kidney-related outcomes (death due to renal failure, end-stage renal disease or sustained 40% or higher estimated glomerular filtration rate from baseline).

To access the publication, click here

Related content
Referral to NHS “Healthier You” programme reduces type 2 diabetes risk
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.